Synairgen plc
Created in 2003
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
2,538 2,460 2,460Activities
Technologies
Entity types
Location
Coxford Rd, Southampton SO16 5YA, UK
Southampton
United Kingdom
Employees
Scale: 51-200
Estimated: 29
Engaged corporates
4
1 1Added in Motherbase
2 years, 11 months ago
biotech Value proposition
We are a specialist respiratory biotech company focused on severe viral lung infections
Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs.
Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.
Breakthrough Science for Severe Viral Lung Infections - Synairgen
Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.
https://www.synairgen.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 PwC Consulting, audit, IT Services and IT Consulting | PwC Consulting, audit, IT Services and IT Consulting | Other 26 Jan 2021 | | |
 London Stock Exchange Finance, Financial Services | London Stock Exchange Finance, Financial Services | Not capitalistic Not partnership Event 12 Oct 2021 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 24 Nov 2016 | | |
 IP Group plc Financial Services | IP Group plc Financial Services | Not capitalistic Not partnership Event 16 Nov 2021 | | |